1. Inicio
  2. Publicaciones
  3. Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer.

Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Edelman, Martin J.
  • Dvorkin, Mikhail
  • Laktionov, Konstatin
  • Navarro, Alejandro
  • Kozlov, Vadim
  • Golden, Gil
  • Jordan, Odette
  • Deng, C. Q.
  • Bentsion, Dmitriy
  • Chouaid, Christos
  • Dechev, Hristo
  • Dowlati, Afshin
  • Fernández Núñez N
  • Ivashchuk, Olexandr
  • Kiladze, Ivane
  • Kortua, Tsira
  • Leighl, Natasha
  • Luft, Aleksandr
  • Makharadze, Tamta
  • Min, YoungJoo
  • Quantin, Xavier
  • DISTINCT Study Investigators

Grupos

Abstract

Topotecan is approved as second-line treatment for small cell lung cancer (SCLC). Irinotecan is also frequently used given its more convenient schedule and superior tolerability. Preclinical studies support disialoganglioside (GD2) as an SCLC target and the combination of dinutuximab, an anti-GD2 antibody, plus irinotecan in this setting. We tested dinutuximab/irinotecan versus irinotecan or topotecan as second-line therapy in relapsed/refractory (RR) SCLC.

Copyright © 2022. Published by Elsevier B.V.

Datos de la publicación

ISSN/ISSNe:
0169-5002, 1872-8332

LUNG CANCER  ELSEVIER IRELAND LTD

Tipo:
Article
Páginas:
135-142
PubMed:
35278766
Factor de Impacto:
1,399 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 34

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Dinutuximab, Disialoganglioside, Irinotecan, Second-line treatment, Small cell

Campos de Estudio

Compartir